{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:06:35Z","timestamp":1754154395642,"version":"3.41.2"},"reference-count":76,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323899413"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2021.07.003","type":"book-chapter","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T23:09:19Z","timestamp":1644448159000},"page":"25-39","source":"Crossref","is-referenced-by-count":2,"title":["Transcriptional configurations of myeloproliferative neoplasms"],"prefix":"10.1016","member":"78","reference":[{"issue":"16","key":"10.1016\/bs.ircmb.2021.07.003_bb0010","first-page":"2114","article-title":"Bellerophontes: an RNA-seq data analysis framework for chimeric transcripts discovery based on accurate fusion model","volume":"28","author":"Abate","year":"2012","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.003_bb0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ccr.2011.10.004","article-title":"The spliceosome as an indicted conspirator in myeloid malignancies","volume":"20","author":"Abdel-Wahab","year":"2011","journal-title":"Cancer Cell"},{"issue":"January","key":"10.1016\/bs.ircmb.2021.07.003_bb0020","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1038\/ncomms10615","article-title":"Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/bs.ircmb.2021.07.003_bb0025","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.003_bb0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-0095","article-title":"Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to Jak inhibitor therapies","volume":"5","author":"Belver","year":"2015","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/bs.ircmb.2021.07.003_bb0035","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-10-1092","article-title":"Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F","volume":"16","author":"Berkofsky-Fessler","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.07.003_bb0040","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.leu.2404730","article-title":"Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis","volume":"21","author":"Bornh\u00e4user","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.003_bb0045","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.humpath.2005.12.002","article-title":"Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation","volume":"37","author":"Bousquet","year":"2006","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.003_bb0050","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/cells9061559","article-title":"Immunotherapy in myeloproliferative diseases","volume":"9","author":"Braun","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.003_bb0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"Suppl. 7","key":"10.1016\/bs.ircmb.2021.07.003_bb0060","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2105-14-S7-S2","article-title":"State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?","volume":"14","author":"Carrara","year":"2013","journal-title":"BMC Bioinf."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.003_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg.2017.96","article-title":"Cancer transcriptome profiling at the juncture of clinical translation","volume":"19","author":"Cie\u015blik","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.003_bb0070","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","article-title":"Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2019 splice site selection through use of a different branch point","volume":"13","author":"Darman","year":"2015","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.003_bb0075","doi-asserted-by":"crossref","first-page":"e1004105","DOI":"10.1371\/journal.pcbi.1004105","article-title":"Transcriptome sequencing reveals potential mechanism of cryptic 3\u2019 splice site selection in SF3B1-mutated cancers","volume":"11","author":"DeBoever","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/bs.ircmb.2021.07.003_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.07.003_bb0085","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrc.2016.51","article-title":"RNA splicing factors as oncoproteins and tumour suppressors","volume":"16","author":"Dvinge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2021.07.003_bb0090","first-page":"1","article-title":"Single-cell transcriptomics in cancer: computational challenges and opportunities","author":"Fan","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.003_bb0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","article-title":"Driver fusions and their implications in the development and treatment of human cancers","volume":"23","author":"Gao","year":"2018","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.07.003_bb0100","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3390\/cells9081901","article-title":"MPN: the molecular drivers of disease initiation, progression and transformation and their effect on treatment","volume":"9","author":"Grabek","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.003_bb0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"ABCR-JAK2 fusion gene as the result of a t(9;22)(P24;Q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"15","key":"10.1016\/bs.ircmb.2021.07.003_bb0110","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.003_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-017-0467-4","article-title":"A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications","volume":"9","author":"Haque","year":"2017","journal-title":"Genome Med."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.003_bb0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"Harbour","year":"2013","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.003_bb0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14728222.2011.538683","article-title":"PCM1\u2013JAK2-fusion: a potential treatment target in myelodysplastic\u2013myeloproliferative and other hemato-lymphoid neoplasms","volume":"15","author":"Hoeller","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.07.003_bb0130","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Holmstr\u00f6m","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.07.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1358334","article-title":"The JAK2 V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy","volume":"6","author":"Holmstr\u00f6m","year":"2017","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.003_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/leu.2016.290","article-title":"The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms","volume":"31","author":"Holmstr\u00f6m","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.003_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","article-title":"Conventional cytogenetics in myelofibrosis: literature review and discussion","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur. J. Haematol."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.07.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-018-0071-8","article-title":"Single-cell RNA sequencing technologies and bioinformatics pipelines","volume":"50","author":"Hwang","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.003_bb0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1593\/neo.06139","article-title":"Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma","volume":"8","author":"Jin","year":"2006","journal-title":"Neoplasia"},{"issue":"02","key":"10.1016\/bs.ircmb.2021.07.003_bb0160","first-page":"1","article-title":"Cancer neoantigens: a promising source of immunogens for cancer immunotherapy","volume":"06","author":"Kitano","year":"2015","journal-title":"J. Clin. Cell. Immunol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.003_bb0165","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/10428194.2017.1359743","article-title":"Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes","volume":"59","author":"Kjaer","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.003_bb0170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"issue":"January","key":"10.1016\/bs.ircmb.2021.07.003_bb0175","doi-asserted-by":"crossref","first-page":"21597","DOI":"10.1038\/srep21597","article-title":"Comparative assessment of methods for the fusion transcripts detection from RNA-seq data","volume":"6","author":"Kumar","year":"2016","journal-title":"Sci. Rep."},{"issue":"5341","key":"10.1016\/bs.ircmb.2021.07.003_bb0180","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.003_bb0185","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.07.003_bb0190","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2014-12-618074","article-title":"The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients","volume":"125","author":"Lau","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.07.003_bb0195","series-title":"Cancer Treatment Reviews","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","author":"Meng","year":"2015"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.003_bb0200","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc3947","article-title":"The emerging complexity of gene fusions in cancer","volume":"15","author":"Mertens","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.07.003_bb0205","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.003_bb0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc2091","article-title":"The impact of translocations and gene fusions on cancer causation","volume":"7","author":"Mitelman","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.07.003_bb0215","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jama.2015.10080","article-title":"Integrative clinical sequencing in the management of refractory or relapsed cancer in youth","volume":"314","author":"Mody","year":"2015","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.003_bb0220","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.leu.2404194","article-title":"T(5;12)(Q23\u201331;P13) with ETV6-ACSL6 gene fusion in polycythemia vera","volume":"20","author":"Murati","year":"2006","journal-title":"Leukemia"},{"issue":"7765","key":"10.1016\/bs.ircmb.2021.07.003_bb0225","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by genotyping of transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"issue":"25","key":"10.1016\/bs.ircmb.2021.07.003_bb0230","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.003_bb0235","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic expression of Sf3b1K700E causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.003_bb0240","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood.2019001334","article-title":"Finding neo (antigens, that is)","volume":"134","author":"Olweus","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/bs.ircmb.2021.07.003_bb0245","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.07.003_bb0250","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"issue":"429","key":"10.1016\/bs.ircmb.2021.07.003_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"22","key":"10.1016\/bs.ircmb.2021.07.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122703","article-title":"Targeting the CALR interactome in myeloproliferative neoplasms","volume":"3","author":"Pronier","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.07.003_bb0265","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol. Cell"},{"issue":"22","key":"10.1016\/bs.ircmb.2021.07.003_bb0270","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.07.003_bb0275","article-title":"Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms","volume":"1","author":"Rice","year":"2011","journal-title":"Blood Cancer J."},{"issue":"7667","key":"10.1016\/bs.ircmb.2021.07.003_bb0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.003_bb0285","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing","volume":"73","author":"Rodriguez-Meira","year":"2019","journal-title":"Mol. Cell"},{"issue":"26","key":"10.1016\/bs.ircmb.2021.07.003_bb0290","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.07.003_bb0295","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/17474086.2017.1380515","article-title":"Mutations in myeloproliferative neoplasms\u2014their significance and clinical use","volume":"10","author":"Schischlik","year":"2017","journal-title":"Expert Rev. Hematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.07.003_bb0300","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.003_bb0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-019-0722-9","article-title":"Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha","volume":"12","author":"Schubert","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"6230","key":"10.1016\/bs.ircmb.2021.07.003_bb0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.003_bb0315","article-title":"Coexistence of P190 BCR\/ABL transcript and CALR 52-Bp deletion in chronic myeloid leukemia blast crisis: A case report","volume":"8","author":"Seghatoleslami","year":"2016","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.07.003_bb0320","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.003_bb0325","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ajh.23659","article-title":"Complex karyotype in a polycythemia vera patient with a novel SETD1B\/GTF2H3 fusion gene","volume":"89","author":"Storlazzi","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.07.003_bb0330","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/leu.2009.167","article-title":"Identification of a novel TEL\u2013Lyn fusion gene in primary myelofibrosis","volume":"24","author":"Tanaka","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.07.003_bb0335","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.07.003_bb0340","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.07.003_bb0345","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/bib\/bbs044","article-title":"Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives","volume":"14","author":"Wang","year":"2013","journal-title":"Brief. Bioinform."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.07.003_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216810","article-title":"Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures","volume":"14","author":"Wong","year":"2019","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/bs.ircmb.2021.07.003_bb0355","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2012.47.8669","article-title":"Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone","volume":"32","author":"Yamada","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"7367","key":"10.1016\/bs.ircmb.2021.07.003_bb0360","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.07.003_bb0365","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1038\/onc.2014.406","article-title":"The landscape and therapeutic relevance of cancer-associated transcript fusions","volume":"34","author":"Yoshihara","year":"2014","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/bs.ircmb.2021.07.003_bb0370","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.07.003_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.77","article-title":"Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with Ruxolitinib and Dasatinib","volume":"5","author":"Zhou","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.07.003_bb0380","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3389\/fonc.2019.01361","article-title":"Development and validation of an RNA-seq-based prognostic signature in neuroblastoma","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.07.003_bb0385","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41408-017-0010-2","article-title":"CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles","volume":"7","author":"Zini","year":"2017","journal-title":"Blood Cancer J."}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms \u2013 Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:21:16Z","timestamp":1753341676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323899413"],"references-count":76,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.07.003","relation":{},"ISSN":["1937-6448"],"issn-type":[{"type":"print","value":"1937-6448"}],"subject":[],"published":{"date-parts":[[2022]]}}}